177 related articles for article (PubMed ID: 26515754)
21. Imaging of Vx-2 rabbit tumors with alpha(nu)beta3-integrin-targeted 111In nanoparticles.
Hu G; Lijowski M; Zhang H; Partlow KC; Caruthers SD; Kiefer G; Gulyas G; Athey P; Scott MJ; Wickline SA; Lanza GM
Int J Cancer; 2007 May; 120(9):1951-7. PubMed ID: 17278104
[TBL] [Abstract][Full Text] [Related]
22. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
Smidt-Hansen T; Folkmar TB; Fode K; Agerbaek M; Donskov F
J Oral Maxillofac Surg; 2013 Sep; 71(9):1532-40. PubMed ID: 23642545
[TBL] [Abstract][Full Text] [Related]
23. Smac therapeutic Peptide nanoparticles inducing apoptosis of cancer cells for combination chemotherapy with Doxorubicin.
Li M; Liu P; Gao G; Deng J; Pan Z; Wu X; Xie G; Yue C; Cho CH; Ma Y; Cai L
ACS Appl Mater Interfaces; 2015 Apr; 7(15):8005-12. PubMed ID: 25815797
[TBL] [Abstract][Full Text] [Related]
24. Targeting efficiency of RGD-modified nanocarriers with different ligand intervals in response to integrin αvβ3 clustering.
Guo Z; He B; Jin H; Zhang H; Dai W; Zhang L; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Biomaterials; 2014 Jul; 35(23):6106-17. PubMed ID: 24794924
[TBL] [Abstract][Full Text] [Related]
25. Surface engineered dendrimers as antiangiogenic agent and carrier for anticancer drug: dual attack on cancer.
Jain K; Jain NK
J Nanosci Nanotechnol; 2014 Jul; 14(7):5075-87. PubMed ID: 24757983
[TBL] [Abstract][Full Text] [Related]
26. PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model.
Li Y; Du Y; Sun T; Xue H; Jin Z; Tian J
BMC Cancer; 2018 Jun; 18(1):669. PubMed ID: 29921237
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study.
Ueno S; Mizokami A; Fukagai T; Fujimoto N; Oh-Oka H; Kondo Y; Arai G; Ide H; Horie S; Ueki O; Kawaguchi K; Shimamura M; Orito M; Ishida T; Ikeda D; Namiki M
Anticancer Res; 2013 Sep; 33(9):3837-44. PubMed ID: 24023317
[TBL] [Abstract][Full Text] [Related]
28. Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients.
Lescaille G; Coudert AE; Baaroun V; Ostertag A; Charpentier E; Javelot MJ; Tolédo R; Goudot P; Azérad J; Berdal A; Spano JP; Ruhin B; Descroix V
Bone; 2014 Jan; 58():103-7. PubMed ID: 24120382
[TBL] [Abstract][Full Text] [Related]
29. Effect of zoledronic acid in an L6-L7 rabbit spine fusion model.
Bransford R; Goergens E; Briody J; Amanat N; Cree A; Little D
Eur Spine J; 2007 Apr; 16(4):557-62. PubMed ID: 16967298
[TBL] [Abstract][Full Text] [Related]
30. Effect of zoledronic acid on osseointegration of titanium implants: an experimental study in an ovariectomized rabbit model.
Yildiz A; Esen E; Kürkçü M; Damlar I; Dağlioğlu K; Akova T
J Oral Maxillofac Surg; 2010 Mar; 68(3):515-23. PubMed ID: 20171470
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms.
Quinn JE; Brown LG; Zhang J; Keller ET; Vessella RL; Corey E
Prostate Cancer Prostatic Dis; 2005; 8(3):253-9. PubMed ID: 15999121
[TBL] [Abstract][Full Text] [Related]
32. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01).
Kim JE; Ahn JH; Jung KH; Kim SB; Kim HJ; Lee KS; Ro JS; Park YH; Ahn JS; Im YH; Im SA; Lee MH; Kim SY
Breast Cancer Res Treat; 2011 Jan; 125(1):99-106. PubMed ID: 20922564
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
[TBL] [Abstract][Full Text] [Related]
34. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.
Ferretti G; Fabi A; Carlini P; Papaldo P; Cordiali Fei P; Di Cosimo S; Salesi N; Giannarelli D; Alimonti A; Di Cocco B; D'Agosto G; Bordignon V; Trento E; Cognetti F
Oncology; 2005; 69(1):35-43. PubMed ID: 16088233
[TBL] [Abstract][Full Text] [Related]
35. PEG-PLA nanoparticles modified with APTEDB peptide for enhanced anti-angiogenic and anti-glioma therapy.
Gu G; Hu Q; Feng X; Gao X; Menglin J; Kang T; Jiang D; Song Q; Chen H; Chen J
Biomaterials; 2014 Sep; 35(28):8215-26. PubMed ID: 24974009
[TBL] [Abstract][Full Text] [Related]
36. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling.
McDonald MM; Dulai S; Godfrey C; Amanat N; Sztynda T; Little DG
Bone; 2008 Oct; 43(4):653-62. PubMed ID: 18582604
[TBL] [Abstract][Full Text] [Related]
37. Integrin αvβ3-targeted dynamic contrast-enhanced magnetic resonance imaging using a gadolinium-loaded polyethylene gycol-dendrimer-cyclic RGD conjugate to evaluate tumor angiogenesis and to assess early antiangiogenic treatment response in a mouse xenograft tumor model.
Chen WT; Shih TT; Chen RC; Tu SY; Hsieh WY; Yang PC
Mol Imaging; 2012; 11(4):286-300. PubMed ID: 22954145
[TBL] [Abstract][Full Text] [Related]
38. Zoledronic acid prevents the tumor-promoting effects of mesenchymal stem cells via MCP-1 dependent recruitment of macrophages.
Jia XH; Du Y; Mao D; Wang ZL; He ZQ; Qiu JD; Ma XB; Shang WT; Ding D; Tian J
Oncotarget; 2015 Sep; 6(28):26018-28. PubMed ID: 26305552
[TBL] [Abstract][Full Text] [Related]
39. Amphiphilic polyelectrolyte/prodrug nanoparticles constructed by synergetic electrostatic and hydrophobic interactions with cooperative pH-sensitivity for controlled doxorubicin delivery.
Huang P; Wang W; Zhou J; Zhao F; Zhang Y; Liu J; Liu J; Dong A; Kong D; Zhang J
ACS Appl Mater Interfaces; 2015 Mar; 7(11):6340-50. PubMed ID: 25746122
[TBL] [Abstract][Full Text] [Related]
40. Bioinspired Nano-Prodrug with Enhanced Tumor Targeting and Increased Therapeutic Efficiency.
Chen WH; Lei Q; Yang CX; Jia HZ; Luo GF; Wang XY; Liu G; Cheng SX; Zhang XZ
Small; 2015 Oct; 11(39):5230-42. PubMed ID: 26285687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
